JP2009537629A5 - - Google Patents

Download PDF

Info

Publication number
JP2009537629A5
JP2009537629A5 JP2009511598A JP2009511598A JP2009537629A5 JP 2009537629 A5 JP2009537629 A5 JP 2009537629A5 JP 2009511598 A JP2009511598 A JP 2009511598A JP 2009511598 A JP2009511598 A JP 2009511598A JP 2009537629 A5 JP2009537629 A5 JP 2009537629A5
Authority
JP
Japan
Prior art keywords
composition
men
fispemifen
effective amount
urethral sphincter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009511598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537629A (ja
JP5123935B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2007/001321 external-priority patent/WO2007135547A2/en
Publication of JP2009537629A publication Critical patent/JP2009537629A/ja
Publication of JP2009537629A5 publication Critical patent/JP2009537629A5/ja
Application granted granted Critical
Publication of JP5123935B2 publication Critical patent/JP5123935B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009511598A 2006-05-22 2007-05-22 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法 Expired - Fee Related JP5123935B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80265706P 2006-05-22 2006-05-22
US60/802,657 2006-05-22
PCT/IB2007/001321 WO2007135547A2 (en) 2006-05-22 2007-05-22 Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis

Publications (3)

Publication Number Publication Date
JP2009537629A JP2009537629A (ja) 2009-10-29
JP2009537629A5 true JP2009537629A5 (enExample) 2011-02-03
JP5123935B2 JP5123935B2 (ja) 2013-01-23

Family

ID=38610674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511598A Expired - Fee Related JP5123935B2 (ja) 2006-05-22 2007-05-22 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法

Country Status (13)

Country Link
US (1) US7825107B2 (enExample)
EP (1) EP2029128B1 (enExample)
JP (1) JP5123935B2 (enExample)
KR (1) KR101505884B1 (enExample)
CN (1) CN101448490A (enExample)
AU (1) AU2007252991B2 (enExample)
BR (1) BRPI0712103A2 (enExample)
CA (1) CA2652783C (enExample)
ES (1) ES2551690T3 (enExample)
MX (1) MX2008014825A (enExample)
NO (1) NO341185B1 (enExample)
RU (1) RU2480207C2 (enExample)
WO (1) WO2007135547A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
USD784972S1 (en) 2014-10-01 2017-04-25 Samsung Electronics Co., Ltd. Portable electronic device
USD779450S1 (en) 2014-10-01 2017-02-21 Samsung Electronics Co., Ltd. Portable electronic device
USD781275S1 (en) 2014-10-01 2017-03-14 Samsung Electronics Co., Ltd. Portable electronic device
USD803818S1 (en) 2014-10-01 2017-11-28 Samsung Electronics Co., Ltd. Portable electronic device
USD779449S1 (en) 2014-10-01 2017-02-21 Samsung Electronics Co., Ltd. Portable electronic device
USD795855S1 (en) 2014-10-01 2017-08-29 Samsung Electronics Co., Ltd. Portable electronic device
USD797713S1 (en) 2014-10-01 2017-09-19 Samsung Electronics Co., Ltd. Portable electronic device
USD785586S1 (en) 2014-10-01 2017-05-02 Samsung Electronics Co., Ltd. Portable electronic device

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (enExample) 1962-09-13
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0260066B1 (en) 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
US4869155A (en) * 1988-07-11 1989-09-26 The Grieve Corporation Airflow distribution system for discharging air from a thin plenum, and oven employing same
US4977906A (en) * 1989-03-07 1990-12-18 Scipio William J Di Diurnal rehabilitation for incontinence trainer
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
US6096874A (en) 1990-10-01 2000-08-01 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives
EP0551434B1 (en) 1990-10-01 1995-11-15 The Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof
US5219548A (en) * 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5196435A (en) * 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5446203A (en) * 1992-08-25 1995-08-29 New York University Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
GB2273704B (en) 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
RU2077889C1 (ru) * 1993-02-24 1997-04-27 Малое государственное предприятие "Флора" Способ лечения хронического простатита
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5658931A (en) * 1994-09-20 1997-08-19 Eli Lilly And Company Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
WO1996016646A1 (en) * 1994-11-29 1996-06-06 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
GB9509572D0 (en) 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
JP2000503991A (ja) 1996-01-29 2000-04-04 イーライ・リリー・アンド・カンパニー 括約筋受容能力を増大させる方法
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
KR20010029519A (ko) 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
ZA982819B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
GB9803521D0 (en) 1998-02-19 1998-04-15 Orion Yhtymo Oy New compounds and pharmaceutical compositions thereof
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413534B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU4701299A (en) * 1998-06-23 2000-01-10 Stuart R. Adler Therapeutic applications of estrogenic carboxylic acids
CA2367895A1 (en) * 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
AU2001271781A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating sphincter incontinence
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
RU2184543C1 (ru) * 2001-05-24 2002-07-10 Московская медицинская академия им. И.М.Сеченова Способ лечения хронического простатита
JP4301763B2 (ja) * 2001-10-31 2009-07-22 藤倉化成株式会社 銀化合物ペースト
MXPA04003866A (es) 2001-11-09 2004-07-08 Pharmacia Ab Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva.
US20040248989A1 (en) * 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms

Similar Documents

Publication Publication Date Title
JP2009537629A5 (enExample)
WO2007089571A8 (en) Method of treating chronic kidney disease
MY164900A (en) Use of an alpha-adrenoceptor antagonist in combination with a muscarinic antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
WO2005113816A3 (en) Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
CL2007001269A1 (es) Compuestos derivados de heterociclos de nitrogeno, moduladores de vias de hedgehog; y uso para el tratamiento de cancer pancreatico, cancer de prostata, meduloblastoma, carcinoma celular basal y cancer pulmonar de celula pequena.
TNSN08147A1 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
ME00937B (me) Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera
PL2559439T3 (pl) Preparat farmaceutyczny do leczenia łagodnego rozrostu gruczołu krokowego
WO2008058239A3 (en) Spink1 as a prostate cancer marker and uses thereof
JP2006517944A5 (enExample)
EP2034835A4 (en) NONTOXIC CANCER WITH A COMBINATION OF ASCORBATE, MAGNESIUM AND A NAPHTHOCHINONE
WO2008070472A3 (en) Use of plasma hsp90 related to malignancy
RU2008150489A (ru) Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы
EP2722060A3 (en) Guanylyl cyclase C ligands
JP2011509956A5 (enExample)
EP2083840A4 (en) IMPROVED TREATMENT FOR BENEFICIAL PROSTATE HYPERPLASIA
JP2008534513A5 (enExample)
TW200630083A (en) Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract
UA56965U (ru) Средство для лечения и профилактики доброкачественной гиперплазии предстательной железы, простатита, импотенции, бесплодия и paka предстательной железы
WO2006005602A3 (en) Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
Rosenberg et al. The signature operator at 2
BE1016292A3 (nl) Verbinding en gebruik bij behandeling.
WO2009045019A3 (en) Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms
IL200899A0 (en) Intravesical apaziquone administration following transurethral resection for treating cancer